Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | +3.45% | +0.22% | -51.66% |
May. 22 | Sector Update: Health Care Stocks Slightly Higher Late Afternoon | MT |
May. 22 | Anavex Life Sciences Expands Leadership Team; Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 368M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -56M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.65
x | P/E ratio 2025 * |
-7.03
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +3.45% | ||
1 week | +0.22% | ||
Current month | +23.29% | ||
1 month | +22.28% | ||
3 months | -10.18% | ||
6 months | -32.84% | ||
Current year | -51.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 4.5 | +3.45% | 796,959 |
24-05-21 | 4.35 | -1.81% | 728,903 |
24-05-20 | 4.43 | -2.64% | 618,500 |
24-05-17 | 4.55 | +1.11% | 942,737 |
24-05-16 | 4.5 | +0.22% | 880,149 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.66% | 368M | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- AVXL Stock